Quarterly report pursuant to Section 13 or 15(d)


9 Months Ended
Mar. 31, 2012
Notes to Financial Statements  

Concentration of Credit Risk

The Company maintains its cash in bank and financial institution deposits in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through March 31, 2012.


Receivable Concentration

As of March 31, 2012, the Company’s receivables were 100% related to reimbursements on GST taxes paid.


Vendor Concentration

As of March 31, 2012, there were two significant vendors that the Company relied upon to conduct its research and development. Both vendors provide services to the Company which can be replaced by alternative vendors should the need arise.


Product and Patent Concentration

As of March 31, 2012 the Company was undertaking preclinical activities for their lead product. The Company was also undertaking research to uncover the mechanism of action of their lead product in order to screen new compounds for development.


The Company has recently been expanded by the filing of an international PCT patent application (No. PCT/AU2010/001403) directed to enhanced proenzyme formulations and combination therapies. The international PCT application has been based on previous provisional patent applications capturing the Company’s ongoing research and development in this area.


Further provisional patent filings are also expected to be filed to capture and protect additional patentable subject matter that is identified, namely further enhanced formulations, combination treatments, use of recombinant products, modes of action and molecular targets.

Foreign Operations


As of March 31, 2012, the Company’s operations are based in Australia.